全球首个!诺诚健华 BTK 启动新自免 III 期临床

求实药社
Feb 11

来源:丁香园Insight数据库2 月 10 日,药物临床试验登记与信息公示平台官网显示,诺诚健华登记了一项在系统性红斑狼疮(SLE)成人患者中评价奥布替尼有效性和安全性的随机、双盲、安慰剂对照、多中心 III 期研究(登记号:CTR20260496)。来源:药物临床试验登记与信息公示平台官网该研究计划纳入484 名受试者,随机分组接受奥布替尼和安慰剂治疗,口服给药,每日一次,为期 52 周。主要...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10